ArticleAmerican journal of physiology. Endocrinology and metabolism2002
AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat.
Article in American journal of physiology. Endocrinology and metabolism, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02694263 (A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Cardiovascular diabetology · 2016Trial
- Carvedilol prevents impairment of the counterregulatory response in recurrently hypoglycaemic diabetic rats.Endocrinology, diabetes & metabolism · 2021Article
- The PI3K/Akt and NF-κB signaling pathways are involved in the protective effects ofRSC advances · 2020Article
- Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.International journal of clinical practice · 2017Review
- Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Current diabetes reviews · 2017 · on this mapReview
- The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.International journal of clinical practice · 2015Review
- Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.P & T : a peer-reviewed journal for formulary management · 2015Article
- Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.Diabetes, obesity & metabolism · 2015Review
- SGLT-2 inhibition and glucagon: Cause for alarm?Trends in endocrinology and metabolism: TEM · 2015Article
- Short commentary on empagliflozin and its potential clinical impact.Therapeutic advances in endocrinology and metabolism · 2015Review
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.Drug design, development and therapy · 2014Review
- Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: a model for weight gain with intensive insulin therapy.American journal of physiology. Endocrinology and metabolism · 2013Article
- BAD modulates counterregulatory responses to hypoglycemia and protective glucoprivic feeding.PloS one · 2011Article
- Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo.Diabetes · 2010Article
- Preparative separation and identification of the flavonoid phlorhizin from the crude extract of Lithocarpus polystachyus Rehd.Molecules (Basel, Switzerland) · 2007Article
- Glucagon secretion and autonomic signaling during hypoglycemia in late pregnancy.American journal of physiology. Regulatory, integrative and comparative physiology · 2006Article
- Insulin signalling downstream of protein kinase B is potentiated by 5'AMP-activated protein kinase in rat hearts in vivo.Diabetologia · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Individuals with type 1 diabetes demonstrate a hypoglycemia-specific defect in glucagon secretion. To determine whether intraislet hyperinsulinemia plays a role in the genesis of this defect, glucagon-secretory responses to moderate hypoglycemia induced by either insulin or a novel combination of the noninsulin glucose-lowering agents 5-aminoimidazole-4-carboxamide (AICAR) and phlorizin were compared in diabetic BB rats (an animal model of type 1 diabetes) and nondiabetic BB rats. The phlorizin-AICAR combination was able to induce moderate and equivalent hypoglycemia in both diabetic and nondiabetic BB rats in the absence of marked hyperinsulinemia. Diabetic BB rats demonstrated impaired glucagon and epinephrine responses during insulin-induced hypoglycemia compared with nondiabetic rats. In contrast, both glucagon (9- to 10-fold increase) and epinephrine (5- to 6-fold increase) responses were markedly improved during phlorizin-AICAR hypoglycemia. Combining phlorizin, AICAR, and insulin attenuated the glucagon response to hypoglycemia by 70% in the diabetic BB rat. Phlorizin plus AICAR had no effect on counterregulatory hormones under euglycemic conditions. We conclude that alpha-cell glucagon secretion in response to hypoglycemia is not defective if intraislet hyperinsulinemia is prevented. This suggests that exogenous insulin plays a pivotal role in the etiology of this defect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.